SpinTech MRI Raises $6.5M in Series A Financing

healthcare

SpinTech MRI, a Bingham Farms, MI-based developer of a quantitative magnetic resonance imaging (MRI) platform, raised $6.5M in Series A funding.

The round was led by Level 8 Ventures and Genesis Innovation Group’s Cultivate Capital Fund.

The company intends to use the funds to expand deployments of the STAGE software for neurologists, radiologists and researchers.

Led by CEO Karen Holzberger, SpinTech MRI provides FDA-cleared STAGE™ (STrategically Acquired Gradient Echo) quantitative magnetic resonance imaging (MRI) platform, which enhances MRI efficiency and clinical value for neurologists, radiologists, and other physicians to improve quality of life and care outcomes for patients with Parkinson’s, Alzheimer’s, dementia, multiple sclerosis, traumatic brain injury (TBI), stroke, cerebral microbleeds (CMB) and other neurological diseases. STAGE integrates between the MRI machine and PACS and does not affect radiologists’ familiar workflows or desktop workspaces. Its rapid image sequencing and processing reduces acquisition time for comprehensive brain imaging by an average of 40 percent, increasing throughput and improving patient experiences. Radiology staff can acquire 16 brain imaging contrasts, including 10 enhanced contrast qualitative outputs and 6 quantitative outputs in just 5 minutes on 3T systems. STAGE also generates standardized image data regardless of scanner brand or model to simplify and improve patient monitoring and data sharing between facilities, and to inform longitudinal and population health studies.

The platform is already deployed at more than 50 hospitals and institutions including the Yale School of Medicine for advanced research, analysis and treatment of Parkinson’s disease and other movement disorders. The system also is used to increase diagnostic accuracy and efficiency for conditions including multiple sclerosis, traumatic brain injury (TBI), stroke and cerebral microbleeds (CMB). STAGE has received 510(k) clearance from the US Food and Drug Administration (FDA) for use on both 1.5T and 3T systems from all MRI manufacturers.

FinSMEs

18/07/2022